GeoVax is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS.

Designed for predominant AIDS virus subtypes using DNA and viral vector technologies, our unique AIDS vaccine technology is designed for use in uninfected people to protect them from AIDS should they be exposed to the HIV-1 virus. GeoVax’s preventive vaccine recently completed Phase 2 safety trials through the US Government sponsored HIV Vaccine Trials Network (HVTN).

Results from preclinical studies demonstrated therapeutic potential for our vaccine. A Phase 1 human clinical trial is now underway where the vaccine is being tested as a treatment to reduce the need for drugs in people already infected with HIV.

As a leader in our field, we are committed to progress against the most devastating global disease of our lifetime.

recent news:

GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update
in Financial - 08/07/2014

GeoVax Announces Clinical Development License Agreement with Valneva SE
in General - 08/06/2014

GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health
in Financial - 07/16/2014

GeoVax Reports 2014 First Quarter Financial Results And Provides Corporate Update
in Financial - 05/01/2014

GeoVax Announces Publication of Repeat Challenge Preclinical Trial in the Journal of Virology
in General - 03/19/2014

GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
in Financial - 03/05/2014

GeoVax Presents at the Phacilitate Vaccine Forum 2014
in General - 01/28/2014

GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases
in General - 01/23/2014

GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected
in General - 01/13/2014

See All News

Search This Site